title: [Aliskiren combined with losartan in type 2-diabetes and nephropathy - secondary publication].
abstract: We evaluated the renoprotective effects of adding aliskiren to treatment with losartan in hypertensive patients with type 2 diabetes and nephropathy. A total of 599 patients were randomized to six months of treatment with placebo or aliskiren in addition to losartan 100 mg and optimal antihypertensive therapy. The primary outcome was a reduction in the urinary albumin-creatinine ratio. Aliskiren 300 mg daily reduced the mean urinary albumin-creatinine ratio by 20% (p < 0.001) compared with placebo. The number of adverse events was similar between groups. Aliskiren is renoprotective independently of its blood pressure lowering effect.
authors.affiliation: Aarhus Universitet, Det Sundhedsvidenskabelige Fakultet, Steno Diabetes Center. hhparving@dadlnet.dk
authors.forename: Hans-Henrik
authors.initials: HH
authors.lastname: Parving
authors.forename: Frederik
authors.initials: F
authors.lastname: Persson
authors.forename: Julia B
authors.initials: JB
authors.lastname: Lewis
authors.forename: Edmund J
authors.initials: EJ
authors.lastname: Lewis
authors.forename: Norman K
authors.initials: NK
authors.lastname: Hollenberg